Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2016;56:339-60. doi: 10.1146/annurev-pharmtox-010715-103617.

Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders.

Author information

1
Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510; email: Amy.arnsten@yale.edu , Min.wang@yale.edu.

Abstract

Medications to treat cognitive disorders are increasingly needed, yet researchers have had few successes in this challenging arena. Cognitive abilities in primates arise from highly evolved N-methyl-d-aspartate (NMDA) receptor circuits in layer III of the dorsolateral prefrontal cortex. These circuits have unique modulatory needs that can differ from the layer V neurons that predominate in rodents, but they offer multiple therapeutic targets. Cognitive improvement often requires low doses that enhance the pattern of information held in working memory, whereas higher doses can produce nonspecific changes that obscure information. Identifying appropriate doses for clinical trials may be helped by assessments in monkeys and by flexible, individualized dose designs. The use of guanfacine (Intuniv) for prefrontal cortical disorders was based on research in monkeys, supporting this approach. Coupling our knowledge of higher primate circuits with the powerful methods now available in drug design will help create effective treatments for cognitive disorders.

KEYWORDS:

Alzheimer's disease; acetylcholine; dopamine; norepinephrine; schizophrenia

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center